***A sneak preview of our 2020 data***
As clinical validity and utility, and of course cost, continue to be key decision points in the widespread adoption of molecular diagnostic systems and instruments, ongoing collaboration between clinical providers and laboratorians is essential for a successful program. The goal should be a consensus on when molecular testing is appropriate, as well as on how the results can and should be interpreted. As technological advances in molecular diagnostics continue toward the promise of personalized medicine, laboratories will further benefit from the rapid translation of established and emerging molecular tests.
Molecular diagnostic platforms enjoy strong satisfaction with an impressive 94% of facilities rating their platforms as excellent or good. Of note, no facility gave its platform(s) a less than satisfactory rating this year.
Of those facilities planning to acquire new platforms or instruments, 30% intend to do so within 1 year. This is up from just 12% last year.
Enter our Sweepstakes now for your chance to win the following prizes:
Just answer the following quick question for your chance to win:
Entries are limited to one entry per person in any active sweepstakes.
Thank you for your entry.